I wonder if all the name brand companies will one day have nothing but generics? (grin). There’s always this interesting topic too, biosimilars. “Because biosimilars aren't exact duplicates of the original drugs, they don't violate the original drug's patent , enabling legal distribution...
Posted to
The Medical Quack .... by Barbara Duck
on 10-16-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, Pharma, Generic Drugs, Marketing, Pfizer, Biosimilars
Update: Are 3 minds better than one? It certainly appears this could be the case, at least when it comes to clinical trials and getting the right type of participants to enroll and some forecasting to make sure the drugs will succeed. What is the target here, the big crystal...
With all the heat of late on financial contributions for CME credit, Pfizer is the first one out of the barrel to restructure where and where they will not offer funding. In other words it appears to be an evaluation process to make sure that the CME funds go where they should, towards education...